1 / 27

Cancer and the immune system

Cancer and the immune system. Lecture 1 Thursday, January 18, 2007 Refs. Kuby Immunology Chapter 21 Basic Pathology 201-205. Review of neoplasia terms. Neoplasm --group of cells that no longer respond to normal growth-control mechanisms May be benign or malignant.

Download Presentation

Cancer and the immune system

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Cancer and the immune system Lecture 1 Thursday, January 18, 2007 Refs. Kuby Immunology Chapter 21 Basic Pathology 201-205

  2. Review of neoplasia terms • Neoplasm--group of cells that no longer respond to normal growth-control mechanisms • May be benign or malignant. • Cancer = a malignant neoplasm • Characteristics are invasion and/or metastasis. • Immunologically, cancer cells are altered self cells.

  3. Classification of cancer • Carcinomas originate from endodermal or ectodermal tissues; >80% of cancers • Hematopoietic malignancies; ~9% of cases • Leukemia: tumor proliferates as individual cells • Lymphoma: cells form solid masses • Sarcomas originate from mesodermal connective tissue; ~1% of cases

  4. Transformation • Normal cultured cells treated with carcinogens or certain viruses have alterations in morphology and growth requirements. • When injected into animals, transformed cells produce tumors. • Transformed cells have cancer-like properties. • Both cancer and transformed cells can be subcultured indefinitely. • Inducing agents--chemicals, viruses, UV irradiation • 2 phases: initiation and promotion • Initiation involves heritable change to genome of cell • Promotion involves stimulation of cell division leads to malignant transformation.

  5. Viruses that induce cancer • DNA viruses • polyoma and SV40 • Human papilloma virus is implicated in over 99% of cervical cancers. • Hepatitis B virus associated with liver carcinoma • Epstein-Barr virus is associated with Burkitt’s lymphoma in Africa and nasopharyngeal carcinoma in Asians. • RNA-retroviruses integrate into host genome • Human T-cell Leukemia virus (HTLV-1) • HIV-1 positive patients have a high incidence of Kaposi’s sarcoma associated with human herpesvirus-8.

  6. Oncogenes • Some retroviruses contain oncogenes (v-onc) • Rous sarcoma virus v-src • avian leukosis virus • Normal cells have sequences homologous to viral oncogenes call cellular oncogenes or proto-oncogenes • c-src is homologous to v-src • Most oncogenes encode proteins that control cell growth.

  7. Groups of genes associated with development of cancer • I Genes that induce proliferation • Growth factors, receptors for growth factors, transcription factors • II Genes that inhibit proliferation • Tumor suppressor genes--RB, p53, etc. • III Genes that regulate programmed cell death • bcl-2 suppresses apoptosis See table 21-1 for organized list of genes and their functions

  8. Role of DNA repair enzymes • Xeroderma pigmentosum-a defect in a gene that encodes DNA repair enzyme. • Cannot repair UV-induced mutations. • High incidence of skin cancer.

  9. Induction of cancer is a multistep process • Steps are well worked out for heritable colon cancer (familial adenomatous polyposis) KI fig. 21-4

  10. Immune surveillance hypothesis • Early 1900s Paul Ehrlich-cancer is frequent but usually eliminated by immune system. • 1950s Lewis--purpose of CM immunity • Evidence for immune surveillance: • Increased cancer in transplant patients taking immunosuppressive drugs appears to support hypothesis. • But no increased cancer in nude mice. Nude mice lack thymus and thus T cells. • Increased cancers were mainly of immune system • Immune surveillance hypothesis remains unproved.

  11. Tumors of the immune system • Leukemia-- proliferation as individual cells • detected by increased number of cells in blood • Lymphoma (lymphosarcoma)-- solid tumor • ALL - acute lymphocytic leukemia • AML - acute myelogenous leukemia • CLL - chronic lymphocytic leukemia • CML - chronic myelogenous leukemia • Acute forms arise in less mature cells. • Good prognosis; permanent remission • Treatment success for all leukemias has greatly increased.

  12. Burkitt’s Lymphoma • A neoplasm of B lymphocytes • Translocations induce c-myc transcription • 75% c-myc from 8 to 14 (Ab heavy chain) • 9% kappa from 2 to 8 • 16% lambda from 22 to 8 • Epstein-Barr virus has gene with homology to bcl-2 and is one factor in development. • EBV makes B cells proliferate. • EBV genome is found in African Burkitt lymphomas • In other areas, EBV causes infectious mononucleosis.

  13. Translocation of c-myc to Ig heavy chain region seen in ~75% of Burkitt lymphoma cases KI 21-3b

  14. Tumor antigens • TSTAs -tumor specific transplantation antigens • Expressed exclusively by tumor cells • TATAs - tumor associated transplantation antigens • Variant forms of normal genes • Antigens usually only expressed at certain times or by certain lineages • Antigens overexpressed

  15. TSTA and TATAs KI 21-6 CEA, AFP

  16. Chemical induction: Different TSTAs for each tumor. No cross protection. Virus induction: Cross protection against tumor cells induced by same virus. No protection if tumor cells induced by a different virus.

  17. Immunization against viral induced tumors KI 21-9 a,b

  18. CTLs from immunized mouse protects against polyoma-induced tumor cells. KI 21-9 c, d

  19. Identification of TSTAs is difficult.The cells with the TSTA do not grow in the mouse but can be detected by CTLs from the mouse. KI 21-7

  20. Newer methods to identify TSTAs KI 21-8

  21. Immune system selects for tumor cells with low TASA/TSTA KI 21-10

  22. Increase costimulation by adding B7 KI 21-11a

  23. Increase costimulation by transfection with GM-CSF KI 21-11b

  24. Cytokine therapy for cancer • Recombinant cytokines tested • IFNa, b, g, IL-1, IL-2, IL-4, IL-5, IL-12, GM-CSF, and TNF • Problems: complexity of cytokine network, local administration, serious side effects

  25. LAK and TIL cells • LAK = lymphokine-activated killer cells • In vitro, culture lymphocytes with tumor antigens and IL-2, reinject the lymphocytes, must infuse IL-2 with LAKs. • TIL = tumor infiltrating lymphocytes • Biopsy tumor, isolate lymphocytes, expand in vitro with IL-2, reinject. • Partial regression

  26. Monoclonal antibodies for cancer treatment • Some antibodies may block TSTAs or TATAs- negative effect. • Antiidiotype antibodies to B cell lymphoma were effective but expensive. (fig.22-14) • Anti-HER2 is used to treat breast cancer. • “Magic bullet” idea - use antibody to deliver toxic agent directly to tumor cell.

More Related